LAS VEGAS, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTC:GLAG), a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotech industry, subsidiary Controlled Environment Genomics Inc., an Akron, Ohio based start-up biotechnology company focused on the development and commercialization of computer controlled digital plant cloning incubators for use in the agricultural and biopharmaceutical industries has partnered with Dr. Katrina Cornish, Professor Department of Horticulture and Crop Science of the Ohio State University, to improve the commercial viability of the TK Dandelion using the Company’s patent pending digital genomics technology to increase the efficiency of the plant's ability to produce natural rubber in the roots. The goal of the research is to use CEG’s proprietary controlled environment genomic CGMP certifiable commercial scale greenhouse systems to cultivate a specific TK dandelion cultivar that has been genetically modified to consistently deliver higher yields, and increased growth rate, resulting in improved commercial viability of producing the crop utilizing indoor controlled environments. CEG and Dr. Cornish have jointly applied this week to the Industrial SEED Grant Partnership Program through OASSRDC, to fund the 2-3 year research collaboration as outlined above.
The OASSRDC Matching Grant Partnership allows CFAES/OARDC researchers to develop relationships with industry partners to engage in innovative research to generate additional private sector support for their research programs, and promote technology transfer between the University and private partners. “I believe that our partnership with the Dr. Cornish lab at OSU/OARDC makes us an ideal candidate for this marching grant program. Gala Global is committed to supporting this research with the goal of building a commercial scale pilot production facility capable of producing over 10,000 tons of natural rubber a year in the rubber capital of the world, Akron, Ohio, with the next 3-4 years,” said Timothy Madden CEO of Gala Global Inc., and founder of CEG Inc.
Gala Global Inc. subsidiary CEG Inc. is also developing breeding tools such as whole genome fingerprinting to enable automated plant breeding (genomic selection) decisions and processes that achieve top-tier plant performance in a sustainable manner.
CEG’s state-of-the-art genomics technology provides the ability to digitally sequence the genomes of the most desirable plant varieties, so the most desirable traits can be used to improve the most commercially viable varieties with traits like increased yield and quality, thus enhancing consumer demand for the product and increasing profitability.
CEG is also developing a proprietary digital genetic database that will be used as an online cloud-based library of digitally sequenced genomes and phenotypic (chemical composition) information on all existing and new plant varieties.
CEG Inc. proprietary digital plant cloning technology will enable geneticists to select the best plant varieties to hybridize, improving and increasing crop quality and yields, by combining the most desirable genetics, maximizing the variation of positive inherited characteristics in each variety.
About Gala Global Inc.
Gala Global, Inc., Anaheim, Calif., is a publicly-traded startup development company specializing in equity investments, debt financing and mergers and acquisitions (M&A) in the biotech industry. Gala Global’s professional services group provides operational services and technologies that drive efficiencies in the market. Gala Global has industry-leading expertise helping companies make the most of their potential in an emerging market. Gala Global website: www.galaglobalinc.com.
About CEG Inc.
Controlled Environment Genomics, Inc. (CEG), Akron, Ohio, is a genomics company with expertise in digital plant gene sequencing, editing and cloning technologies. CEG is a subsidiary of Gala Global Inc., Anaheim, Calif., a publicly-traded development firm specializing in equity investments, debt financing and mergers and acquisitions in the biotechnology industry. CEG’s state-of-the-art genomics technology enables computerized genome sequencing and plant cloning using a fully automated turnkey solution for digitally sequencing the genomes of the world’s most desirable plant varieties based on flavor and nutrition. CEG improves the most valuable crop varieties currently available on the market by utilizing proprietary Cloud computing-based digital cloning technologies to crossbreed crops that have advantageous traits with established varieties featuring the best genetic profiles for commercial production. The very best plant traits can be used to improve the most sought-after commercial varieties by adding characteristics like maximized yields and quality conducive to increased consumer demand and optimized production profitability. www.galaglobalinc.com.
Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
Contact:
Timothy J. Madden, CEO
Gala Global, Inc.
tim@galaglobalinc.com
www.galaglobalinc.com
(714) 660-3081